Percutaneous Coronary Intervention

Novel healing-targeted drug-eluting stent (HT-DES; BuMA Supreme, Sinomed) vs. durable polymer everolimus-eluting stents for PCI.

Primary PCI was associated with positive outcomes in patients with STEMI and cancer, but was underutilized, according to study data published in European Heart Journal: Acute Cardiovascular Care.

Women had lower incidences of MI and underwent fewer invasive treatments compared with men, according to study data published in Mayo Clinic Proceedings.

Boston Scientific announced it received FDA approval for its drug-eluting stent system designed to treat large, proximal vessels.

Default option interventions were associated with a significant increase in cardiac rehabilitation referrals for patients with ischemic heart disease, according to findings published in JAMA Network Open.

Evolocumab, a PCSK9 inhibitor, in addition to statin therapy for stable atherosclerotic CVD may lower risk for future revascularization with PCI or CABG, according to findings published in the Journal of the American College of Cardiology.

Due to the COVID-19 pandemic, the Transcatheter Cardiovascular Therapeutics meeting was held virtually. TCT Connect, which ran from Oct. 14 to 18, offered the latest in cutting-edge science for interventional cardiologists.

Time from MI symptom onset to PCI may be a stronger predictor of infarct size and microvascular obstruction than door-to-balloon time in patients with STEMI, researchers reported.

Patients who filled out 90-day rather than 30-day prescriptions demonstrated higher adherence and infrequent medication changes following post-MI hospital discharge, researchers reported.

Among patients who underwent PCI with a sirolimus-eluting stent, short-term and long-term dual antiplatelet therapy conferred similar rates of target vessel failure, researchers reported.